Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01433731 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Phase 1 study, sponsored by TetraLogic Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01433731: Completed Phase 1 study, sponsored by TetraLogic Pharmaceuticals.
NCT01433731 is a Phase 1 study that has completed, run by TetraLogic Pharmaceuticals. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01433731, a Phase 1 study, has completed, sponsored by TetraLogic Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and tolerability of topical SHP141 applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients with Stage IA, IB, or IIA CTCL.
Interventions
- DRUG placebo for SHAPE (SHP-141)
- DRUG SHAPE (SHP-141) 0.1% BID
- DRUG SHAPE (SHP-141) 0.5% BID
- DRUG SHAPE (SHP-141) 1.0% BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01433731
The ClinicalTrials.gov registry entry for NCT01433731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TetraLogic Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo for SHAPE (SHP-141) is the first listed.
NCT01433731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01433731 about?
NCT01433731 is a clinical study titled "Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)". The purpose of this study is to investigate the safety and tolerability of topical SHP141 applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients with Stage IA, IB, or IIA CTCL...
What is the current status of trial NCT01433731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-11. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01433731?
The interventions under investigation include: placebo for SHAPE (SHP-141) (DRUG), SHAPE (SHP-141) 0.1% BID (DRUG), SHAPE (SHP-141) 0.5% BID (DRUG), SHAPE (SHP-141) 1.0% BID (DRUG).
Who is sponsoring clinical trial NCT01433731?
This trial is sponsored by TetraLogic Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.